Life Sciences Tools & Services
Price
$113.76
+0.82%Market Cap
$12.69B
Day High
$114.50
Day Low
$112.19
RVTY delivered 7.0% revenue growth to $711.1M in Q2 2026, but net income slipped 3.6% to $40.7M as cost of revenue rose faster than sales and cash balances declined 24.4% year-over-year.
Key risk: Surge in Current Liabilities Creates Liquidity Pressure
Current liabilities increased 91.1% YoY to $1.24B, likely due to near-term debt maturities, while cash and equivalents fell 24.4% to $860.3M. Although the current ratio remains above 1.0x at 1.72x, the rapid shift in liability structure could strain liquidity if refinancing conditions are unfavorable.
Other Health Care Equipment companies